A Phase 1 interventional study of TD-9855 and Fluvoxamine in Drug Drug Interaction (DDI), sponsored by Theravance Biopharma. Completed at 1 site in United States. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-14.
Sponsored by Theravance Biopharma (part of Zymeworks) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 899 studies in Smoking with a site in United States — 90 open to participants now, 110 under way, 4 of them phase 3. Smoking · United States.
Among the 899 studies in Smoking with a site in United States, this one is the 587th largest by enrollment of the 785 interventional ones that give a count, is one of 38 that started in 2018, is one of 67 in phase 1, and was the 593rd registered.
1,516 studies on the registry are indexed under Smoking; 196 are open to participants now.
Browse Smoking studies →90 of the 899 studies in Smoking with a site in United States are open now. Recruiting first, the newest first:
RAI Services Company · Sites in United States
Ages 21–65 · Healthy volunteers
RAI Services Company · Sites in United States
Ages 21–65 · Healthy volunteers
VA Office of Research and Development · Sites in United States
Ages 18+
Georgia State University · Sites in United States
Ages 21+ · Healthy volunteers
University of California, Irvine · Sites in United States
Ages 50–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 143 Smoking studies recruiting now, 74 (52%) set no upper age limit and 51 (36%) stop at 75 or younger; 3 take children under 18; 68 take healthy volunteers.
This study: 19 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
899 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 89 · Phase 2 113 · Phase 3 64 · Phase 4 67
First in 1993; this study’s year is marked. 38 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 116 across 1,167 interventional studies indexed under Smoking.
Median enrollment 109 across the 785 interventional studies, 131 across the 108 observational. Of the 742 that completed or were terminated, 293 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
101 of 899 have an industry lead sponsor. The 10 most frequent:
This study is registered under Theravance Biopharma, one of the names counted as Zymeworks. Under that name alone:
Theravance Biopharma is the lead sponsor of 47 studies on the registry; none are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 11 (46%) have results posted.
Zymeworks has 1 study filed under Smoking — fewer than ten, so there is no comparison to draw.
56 of the studies in Smoking with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07119489Wake Forest University Health SciencesA Novel Dialectical Behavior Therapy Brief Group Intervention for Cigarette Smoking by Patients With Cancer: An Open Clinical Trial | 2026-11 |
| NCT06945120Dana-Farber Cancer InstituteACT Lung Health Intervention: Phase Two | 2026-11-30 |
| NCT04968249University of MichiganMichigan Early Disease Progression Cohort | 2026-12 |
| NCT07710820RAI Services CompanyA Multi-Site Study to Assess the Effect of Availability of a Heated Tobacco Product on Smoking Abstinence Among Current Primary Cigarette Smokers | 2026-12 |
| NCT06837220University of ChicagoImplementation of Tobacco Cessation Programming at Community Behavioral Health Sites | 2026-12 |
Add all 56 to your calendar (.ics) → With an account.
Among the 899 studies in Smoking with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to assess the effect of fluvoxamine, itraconazole and smoking on the PK disposition of multiple doses TD-9855 in healthy male subjects. The study will also assess the relationship between caffeine PK and TD-9855 PK disposition in healthy male smokers and non-smokers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Male smokers will receive TD-9855, fluvoxamine, and caffeine
Drug: TD-9855 · Drug: Fluvoxamine · Drug: Caffeine
Male non-smokers will receive TD-9855, itraconazole, and caffeine
Drug: TD-9855 · Drug: Itraconazole · Drug: Caffeine
oral tablet, QD
oral tablet, QD
oral tablet solution, QD
oral solution, single dose
Change in TD-9855 plasma exposure when administered with itraconazole or fluvoxamine
Time frame: Day 9 and Day 24
Correlation between caffeine PK disposition and TD-9855 plasma exposure
Correlation co-efficient will be calculated between caffeine/paraxanthine ratio at 4hr after caffeine dose and TD-9855 plasma AUC on Day 9 and Day 24.
Time frame: Day 9 and Day 24
Plan to share: No — Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.
No publications or documents are linked to this record.
Ran from Feb 2018 to primary completion in Apr 2018, 1 month.
Of 34 phase 1 interventional studies under Smoking, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 49. This study's 1 month is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ampreloxetine · Fluvoxamine